CLINICAL TRIALS PROFILE FOR NUZYRA
✉ Email this page to a colleague
All Clinical Trials for NUZYRA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03757234 ↗ | IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis | Completed | Paratek Pharmaceuticals Inc | Phase 2 | 2018-11-19 | The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis. |
| NCT04144374 ↗ | Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis | Completed | Paratek Pharmaceuticals Inc | Phase 1 | 2020-02-10 | This study will determine the tissue penetration of the novel tetracycline antibiotic, omadacycline (Nuzyra, Paratek Pharmaceuticals, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants. |
| NCT04144374 ↗ | Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis | Completed | Hartford Hospital | Phase 1 | 2020-02-10 | This study will determine the tissue penetration of the novel tetracycline antibiotic, omadacycline (Nuzyra, Paratek Pharmaceuticals, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants. |
| NCT04779242 ↗ | Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia | Recruiting | Paratek Pharmaceuticals Inc | Phase 3 | 2021-02-25 | The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia. |
| NCT04922554 ↗ | Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) | Recruiting | Paratek Pharmaceuticals Inc | Phase 2 | 2021-10-15 | The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc) |
| NCT05217537 ↗ | Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections | Not yet recruiting | Paratek Pharmaceuticals Inc | Phase 1 | 2022-01-01 | The purpose of this study is to evaluate the pharmacokinetics of a single dose of intravenous or oral omadacycline in children and adolescents with suspected or confirmed bacterial infections. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NUZYRA
Condition Name
| Condition Name for NUZYRA | |
| Intervention | Trials |
| Mycobacterium Abscessus Infection | 1 |
| Mycobacterium Infections, Nontuberculous | 1 |
| Nontuberculous Mycobacterial Lung Disease | 1 |
| Nontuberculous Mycobacterial Pulmonary Infection | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for NUZYRA
Trials by Country
Clinical Trial Progress for NUZYRA
Clinical Trial Phase
Clinical Trial Sponsors for NUZYRA
Sponsor Name
